Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by Gbathaton Apr 22, 2021 6:47pm
239 Views
Post# 33052580

The future looks ProMISing here

The future looks ProMISing here1. The company appears to be very close to rolling out a 50-50 joint venture (immusafe) to launch a COVID serology test that can assess ones level of immunity to various known and emerging variants of SARS COV2.  Meanwhile, we are (sadly) hearing more and more news about variants and waning immunity with COVID, be that immunity vaccine induced or due to previous infection.  Supporting evidence: a.) listing of SARS COV2 assay on the requisition forms for BC Neuroscience, alongside their array of accredited diagnostic tests.  b.) accidental (we presume) publication of their immusafe website content, which gave a glimpse of an exciting product and a potentially lucrative business model

2. The company recieved a $7M USD investment from sports magnates in the Boston area with deep connections to the Alzheimer's Disease research field.  The PR about the investment cited due diligence performed on behalf of the investors indicated great technical potential for PMN310 and the ProMIS platform.

3. Biogen continues to garner support for FDA approval of aducanumab, which would be the first amyloid beta targeting AD drug and lay the foundation for ProMIS's PMN 310 clinical trials and associated investments.


This board continues to be polluted with negativity, perhaps trying (and succeeding) to keep the price down.  I have most of them on ignore, but occasionally I log out and see all the lovely posts by farmerjane et al.  I used to think that this board impacts the share price.  After the recent flurry of good news on this board and lack of share price movement, I'm beginning to think this is just a therapeutic echo chamber for those who either love or hate this stock.  Oh, and News flash farmerjane- I am not Elliot and have no affilliation with PMN other than being a heavily (for me) invested fanboy. I'm actually in the states and have ---,--- shares of ARFXF.  Maybe it will work out and I'll start that non-profit organization I've always dreamed of, maybe it won't and I'll keep working my fingers to the bone until I retire.  But please try to see both sides and have some grace in the process. I'll try to do the same.  Perhaps you bought in high and lost big- I am sorry about that.  I had the resources to average down to where I am currently ahead.  But I am not selling anything yet.  I'll get my initial investment (20% of shares) out at the right time, which I hope is coming soon, and then ride the rest into the unknown future.  


<< Previous
Bullboard Posts
Next >>